DBP International: Out-licensing to YRRO rights for an international patent for the use of ferrous succinate
Double Bond Pharmaceuticals AB (publ) (“DBP”) has entered into an agreement with YRRO Ltd (“YRRO”) to sell the license for use of its intellectual properties including international patent application for active substance ferrous succinate, marketed as “Inofer”, in the USA, Japan, China and the EU (excluding the Nordic countries). Clinical trial results undertaken by DBP indicate that ferrous succinate (“Inofer”) markedly and significantly improved iron uptake, iron saturation, and iron stores in patients with heart failure and iron deficiency. Inofer is a low-cost oral alternative to
